BIBS 39
Based on 1 Customer Validation
BIBS 39 is a non-peptide angiotensin II receptor antagonist with antihypertensive activity, with higher affinity for the AT1 receptor than for the AT2 receptor. BIBS 39 competitively blocks AT1-mediated vasoconstriction and pressor responses, and effectively inhibits the activity of the renin-angiotensin-aldosterone system. BIBS 39 reduces diastolic blood pressure and induces mild, transient reflex tachycardia, with no off-target functional activity on the norepinephrine, K+/Cl− or vasopressin pathways. BIBS 39 can be used in research related to hypertension and renal hypertension[1][2][3].
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.70%
- CAS 番号: 133085-33-3
- 分子式: C32H36N4O3
- 分子量:524.65
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-B0205
CandesartanAngiotensin II AT1-Receptor Blocker -
HY-17512
LosartanAngiotensin II Receptor Antagonist -
HY-15778
AVE 0991Ang-(1-7) Receptor Agonist -
HY-18204
ValsartanAngiotensin II Receptor Antagonist -
HY-14914
AzilsartanAT1 Antagonist -
HY-18204A
Sacubitril/ValsartanARN Inhibitor -
HY-14736
Azilsartan medoxomilAngiotensin Receptor Antagonist -
HY-13955
TelmisartanAngiotensin II Type 1 Receptor -
HY-17004
OlmesartanAT1R Antagonist -
HY-B0780
FimasartanAngiotensin Receptor Antagonist -
HY-17005
Olmesartan medoxomil -
HY-17505
Candesartan CilexetilAngiotensin II receptor Inhibitor
Angiotensin Receptor アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
[1]|
AT2 Receptor |
AT1 Receptor |
体外実験
BIBS 39 (60 min) shows high affinity for AT1 receptors in rat lung membranes (Ki=29 nM) and 17-fold selectivity for AT1 over AT2 receptors in rat adrenal medulla membranes[1].
BIBS 39 (10-8-10-6 M; 30 min) acts as a competitive AII receptor antagonist in isolated rabbit aortic rings, with a pA2 value of 8.14, and does not affect contractions induced by noradrenaline or KCl at 10-5 M[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
BIBS 39 (0.03-30 mg/kg; i.v.; cumulative doses at 15-minute intervals, single dose) is an effective antihypertensive agent in conscious renal hypertensive rats, with an ED30 of 2.0 mg/kg i.v. and a 25-minute duration of action at a 1 mg/kg i.v. dose[2].
BIBS 39 (1-10 mg/kg; i.v.; single dose) dose-dependently antagonizes AII-induced cardiovascular effects in propranolol-treated pithed rabbits, with a 10 mg/kg i.v. dose significantly reducing basal diastolic blood pressure and heart rate[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats (male, 220-260 g, pithed)[1]
-
Dosage:0.3 mg/kg; 1 mg/kg; 3 mg/kg; 10 mg/kg
-
Administration:i.v.; single dose
-
Result:Lowered diastolic blood pressure by 7.7 mmHg at 0.3 mg/kg, 10.0 mmHg at 1 mg/kg, 11.8 mmHg at 3 mg/kg, and 11.8 mmHg at 10 mg/kg.
Caused parallel rightward shifts of the AII log dose-pressor response curve with shift factors of 4.5 (0.3 mg/kg), 11.8 (1 mg/kg), 55.8 (3 mg/kg), and 228.3 (10 mg/kg).
Did not affect heart rate at any dose.
Did not alter log dose-pressor response curves for noradrenaline or vasopressin at 3 mg/kg.
Showed no agonistic activity (no increase in diastolic blood pressure).
-
Animal Model:Wistar (male, 135-145 g, two-kidney, one-clip renal hypertension model)[2]
-
Dosage:0.03 mg/kg; 1 mg/kg; 3 mg/kg; 10 mg/kg; 30 mg/kg
-
Administration:i.v.; cumulative doses at 15-minute intervals (dose-response study); single dose (duration study)
-
Result:Caused a significant, dose-dependent decrease in diastolic blood pressure (DBP).
Reduced DBP by 5-6 mmHg at 0.03 mg/kg i.v.
Achieved maximal DBP reduction of ~46 mmHg at 10 mg/kg i.v.
Had an ED30 (dose lowering DBP by 30 mmHg) of 2.0 mg/kg i.v.
Showed no significant additional DBP reduction when captopril was administered after its maximal hypotensive dose.
Caused a significant, dose-dependent increase in heart rate (HR); increased HR by 40 beats/min at 10 mg/kg i.v.
Reduced DBP by 15.8 mmHg at 1 minute post-injection of 1 mg/kg i.v. dose.
Reached maximal DBP reduction of 25.5 mmHg at 3 minutes post-injection of 1 mg/kg i.v. dose.
Maintained antihypertensive effect for 25 minutes after 1 mg/kg i.v. dose.
Induced a small, transient HR increase of 30 beats/min at 3 minutes post-injection of 1 mg/kg i.v. dose.
-
Animal Model:New Zealand White (male, 1.4-1.8 kg, pithed, propranolol pretreated)[3]
-
Dosage:1 mg/kg; 3 mg/kg; 10 mg/kg
-
Administration:i.v.; single dose
-
Result:Produced basal diastolic blood pressure (DBP) of 30 mmHg, left ventricular pressure (LVP) of 50 mmHg, left ventricular end-diastolic pressure (LVEDP) of -2.6 mmHg, dP/dtmax of 1,700 mmHg/s, and heart rate (HR) of 210 beats/min at 1 mg/kg i.v.
Produced basal DBP of 21 mmHg, LVP of 48 mmHg, LVEDP of -1.5 mmHg, dP/dtmax of 1,500 mmHg/s, and HR of 214 beats/min at 3 mg/kg i.v.
Caused statistically significant reduction in basal DBP (16 mmHg, p < 0.05 vs. propranolol-only group) and statistically significant reduction in basal HR (204 beats/min, p < 0.05 vs. propranolol-only group), alongside LVP of 46 mmHg, LVEDP of -1.8 mmHg, and dP/dtmax of 1,460 mmHg/s at 10 mg/kg i.v.
Caused parallel, rightward shifts of angiotensin II-induced dose-response curves for DBP and LVEDP without altering maximal angiotensin II-induced responses across all doses.
化学情報
-
CAS 番号 133085-33-3
-
性状 Solid
-
分子量 524.65
-
分子式 C32H36N4O3
-
Color White to off-white
-
SMILES
O=C(C1=CC=CC=C1C2=CC=C(CN3C4=CC(NC(NC5CCCCC5)=O)=CC=C4N=C3CCCC)C=C2)O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
溶剤 & 溶解度
体外:
DMSO : ≥ 32 mg/mL (60.99 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1.25 mg/mL (2.38 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1.25 mg/mL (2.38 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (280 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
[2]. Zhang J, et al. Antihypertensive activity of the novel, nonpeptide angiotensin II receptor antagonists BIBS 39 and BIBS 222 in conscious renal hypertensive rats. Pharmacology. 1993;46(5):241-247. [Content Brief]
[3]. Zhang J, et al. Hemodynamic effects of angiotensin II and the influence of angiotensin receptor antagonists in pithed rabbits. J Cardiovasc Pharmacol. 1995;25(5):724-731. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9060 mL | 9.5302 mL | 19.0603 mL | 47.6508 mL |
| 5 mM | 0.3812 mL | 1.9060 mL | 3.8121 mL | 9.5302 mL | |
| 10 mM | 0.1906 mL | 0.9530 mL | 1.9060 mL | 4.7651 mL | |
| 15 mM | 0.1271 mL | 0.6353 mL | 1.2707 mL | 3.1767 mL | |
| 20 mM | 0.0953 mL | 0.4765 mL | 0.9530 mL | 2.3825 mL | |
| 25 mM | 0.0762 mL | 0.3812 mL | 0.7624 mL | 1.9060 mL | |
| 30 mM | 0.0635 mL | 0.3177 mL | 0.6353 mL | 1.5884 mL | |
| 40 mM | 0.0477 mL | 0.2383 mL | 0.4765 mL | 1.1913 mL | |
| 50 mM | 0.0381 mL | 0.1906 mL | 0.3812 mL | 0.9530 mL | |
| 60 mM | 0.0318 mL | 0.1588 mL | 0.3177 mL | 0.7942 mL |
BIBS 39 関連分類
HY-19732 関連分類
Powered by Bioz